Reprograming the tumor microenvironment is a promising strategy to overcome resistance to immune checkpoint inhibitors (ICI) in patients with malignant melanoma. Here, the authors report a phase 1/2 study evaluating the combination of LOAd703 (viral-vector encoding CD40L and 4-1BBL) with atezolizumab (anti-PD-L1) in patients with ICI-resistant, malignant melanoma.
- O. Hamid
- V. Ekström-Rydén
- GJ Ullenhag
